News Focus
News Focus
icon url

ilovetech

08/08/23 9:07 PM

#618629 RE: Doc logic #618616

Doc - That was a well laid out commentary which I know you've touched on numerous times before, but it's important for those who are newer to the stock to be enlightened to those earlier tealeaves. I think it's worth noting what the likely relationship dynamics are between NWBO and the RA's. We're looking at a pioneering class of treatment which includes both treatment modality compositions and it's respective manufacturing optimization technology. Let's be clear, the clock punchers at these RA's couldn't dream of doing circles around the folks, who in this case are like the highest trained pilots in the world, who've trained their whole lives for this unique opportunity to land a brand new model plane on the tarmac. The RA's are more like the crew who know enough, but not enough to know, not to stand in the way. Not when LL is in the Captain's chair.

ILT
icon url

Riley4

08/08/23 10:06 PM

#618644 RE: Doc logic #618616

What I cant understand is why regulatory let or make placebo pt’s crossover but now waiting yrs later for all those not in trials die, seriously, they say unfair not give a chance but now all others c gbm? This is so ironic
icon url

learningcurve2020

08/09/23 9:10 AM

#618718 RE: Doc logic #618616

Doc, how many patients do you suppose who were rejected due to the screening criteria were sent on to the study group / compassionate use / Specials?